Vortioxetine Improves Depressive Symptoms and Cognition in Parkinson’s Disease Patients with Major Depression: An Open-Label Prospective Study

Santos‐García, Diego; Losada, Maria G. Alonso; Hernando, Icíar Cimas; Cabo, Iria; Baña, Rosa Yáñez; Redondo, Ruben Alonso; González, Jose Manuel Paz; Bartolomé, Carlos Cores; Painceiras, Maria J. Feal; Alvarado, María Cristina Íñiguez; Labandeira, Carmen M.; Díaz, Iago García

doi:10.3390/brainsci12111466

Cited by 7 publications

(1 citation statement)

References 62 publications

(75 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Vortioxetine has been shown to be well-tolerated and efficacious in patients with MDD and comorbid physical conditions, such as cardiovascular disease, diabetes mellitus, Parkinson’s disease [ 53 ] and, to a lesser extent, chronic obstructive pulmonary disorders (COPD) [ 54 ]. Notably, vortioxetine’s effectiveness and tolerability extend to older populations, who often deal with multiple comorbidities and polypharmacy [ 55 ].…”

Section: Methodsmentioning

confidence: 99%

Individualized strategies for depression: narrative review of clinical profiles responsive to vortioxetine

Cuomo,

Aguglia,

De Berardis

et al. 2024

Ann Gen Psychiatry

View full text Add to dashboard Cite

Background Depression is a highly heterogeneous disorder, often resulting in suboptimal response and remission rates. This underscores the need for more nuanced clinical characterization of patients to tailor individualized treatment plans. Emerging evidence highlights the critical role of cognitive and emotional dysfunction in major depression, prompting the exploration of novel therapeutic interventions that target these specific symptom domains. Main text Vortioxetine, a multimodal antidepressant, enhances serotonergic activity while also modulating several other neurotransmitter systems involved in depressive symptoms such as emotional blunting, anhedonia, and cognitive dysfunction. Numerous randomized, placebo-controlled trials have demonstrated vortioxetine’s efficacy and safety in treating depression, particularly in specific subgroups of depressed patients, including those with cognitive deficits and comorbid anxiety symptoms or disorders. Although not randomized or placebo-controlled, studies have also shown vortioxetine’s efficacy in depressed patients with emotional blunting or anhedonia. Vortioxetine’s ability to effectively treat a range of depressive symptoms, including anhedonia, emotional blunting, anxiety, and cognitive dysfunction, provides an individualized treatment solution for depressed individuals suffering from these symptoms. The purpose of this paper is to identify clinical profiles of patients who may benefit from vortioxetine, with the goal of optimizing therapeutic outcomes. Conclusion Vortioxetine has been shown to be effective for patients with depression and symptoms such as anhedonia, emotional blunting, anxiety, and cognitive dysfunction. Tailoring treatment plans to individual needs and personalizing treatment choices based on the specific symptoms presented by depressed patients improve treatment outcomes.

show abstract

Section: Methodsmentioning

confidence: 99%